|Bid||0.00 x 3000|
|Ask||0.00 x 1000|
|Day's Range||61.90 - 62.08|
|52 Week Range||53.83 - 64.65|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
The healthcare sector will continue to see political attention in the remainder of 2018, with the 2017 U.S. tax reform bill influencing it in a number of ways. Its repeal of mandated healthcare is likely to change demand and effect provider participation.
Merck (MRK) reported its second-quarter earnings on July 27. Merck generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year (or YoY) growth. In the second quarter, Merck’s Pharmaceuticals segment generated revenues of $9.3 billion compared to $8.8 billion in the second quarter of 2017, reflecting ~6.0% YoY growth. Merck’s Animal Health segment generated revenues of $1.1 billion in the second quarter, reflecting ~14.0% YoY growth.
Changing political winds and the seasonal period for drugmakers to hike their prices could trigger short-term volatility in pharmaceutical sector-related ETFs. The markets could put a spotlight on pharmaceutical stocks and the rising cost of drug prices as Mid-term elections are quickly coming up in November and July is a popular month for drug companies to increase list prices on medicines, writes Charley Grant for the Wall Street Journal. Just last week, Health and Human Services Secretary Alex Azar said in congressional testimony that companies should “practice restraint” with price increases.
Pharmaceutical ETFs are securities that are publicly traded on the stock market and designed for investors wanting to diversify their investments in the pharmaceutical sector.
Generally speaking, pharmaceuticals are experiencing a mixed year. After a promising start where Biogen shares closed out January up more than 8%, the momentum quickly collapsed. It wasn’t until the prior month that BIIB stock began to recover from its mess.
GlaxoSmithKline’s (GSK) product portfolio is segregated into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline reported a 2% YoY (year-over-year) fall in revenue to ~7.2 billion British pounds in Q1 2018 compared to Q1 2017.
In 1Q18, Merck’s (MRK) human vaccines business saw its total revenue grow 4.2% YoY (year-over-year) to $1.5 billion from $1.4 billion. Its Gardasil franchise includes vaccines used to prevent strains of sexually transmitted HPV (human papillomavirus) infections that cause genital warts and have been linked with cervical, vulvar, anal, penile, and vaginal cancer.
Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.
GlaxoSmithKline’s (GSK) product portfolio is divided into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline reported revenues of ~7.2 billion pounds in 1Q18, a ~2% decline compared to 1Q17. However, all three segments reported growth in operating revenues in 1Q18.
Sanofi (SNY) missed Wall Street analysts’ estimates for revenues today but beat estimates for earnings per share (or EPS). It reported EPS of 1.28 euros on revenues of ~7.9 billion euros, compared to estimates for EPS of 1.13 euros on revenues of 8.1 billion euros for 1Q18.
Johnson & Johnson (JNJ) surpassed EPS (earnings per share) and revenue estimates in 1Q18. For 1Q18, Johnson & Johnson reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against the estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q18.
GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.
Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.
Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products.
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company with headquarters in Brentford, Middlesex. The company classifies its business portfolio into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
VanEck announced today its regular distributions per share for its VanEck Vectors® equity exchange-traded funds.